Commentary: Can stem cell therapy reshape pharma's sales model?
This article was originally published in Scrip
The pharmaceutical industry's foray into the new and rapidly evolving field of stem cell therapies will require an approach to commercialisation untested on traditional pharmaceutical medicines, say Andrew Millest, Su Webber and Mark Williams
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.